A model for prognosis of development of left ventricular systolic dysfunction in patients with acute myocardial infarction and type 2 diabetes mellitus taking into account tenascin C level

Authors

  • M. Yu. Koteliukh Kharkiv National Medical University,

DOI:

https://doi.org/10.14739/2310-1210.2016.2.69169

Keywords:

Myocardial Infarction, Tenascin С, Diabetes Mellitus Type 2, Left Ventricular Dysfunctio

Abstract

The aim of the study was to elaborate a model for prediction of development of left ventricular systolic dysfunction in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus taking into account tenascin C level and estimation of predictive value of this indicator in AMI.

Methods and materials. 120 patients were included into the study. Tenascin C and troponin I were determined by ELISA method (Immuno-Biological Laboratories Co. Ltd. (IBL), Takasaki-Shi, Japan; XEMA, Moscow, Russia). Statistical processing of the results was performed with Statistica 6.0 software. Prediction properties were evaluated by ROC-curve. The model was elaborated using reduced ejection fraction (EF) in patients with AMI, analyzing indicators of lipid, carbohydrate metabolism, age, matrix metalloproteinases, tenascin C. Stepwise logistic regression method was used to allocate four indices, which may be employed for reliable accuracy prediction, namely diastolic blood pressure (DBP), creatinine, body mass index (BMI), tenascin C.

Results: Results of the study provided evidence that type 2 diabetes mellitus is associated with decompensation impact of tenascin C in patients with AMI. The study found a correlation between tenascin C and troponin I. Patients with AMI and type 2 diabetes mellitus had association between tenascin C and troponin I – r = -0.26 (p<0.05) and in AMI patients without type 2 DM – r = 0.28 (p<0.05). Consideration of tenascin C, creatinine, BMI and DBP indices in one model makes it possible to increase the specificity to 77% in high sensitivity of 89%.

Conclusion. Application of the model taking into account tenascin C level can be considered to predict development of left ventricular systolic dysfunction in patients with AMI and type 2 diabetes mellitus.

References

Bogomolov, A. V., & Kukushkin, Yu. A. (2013) Tekhnologiya ROC-analiza kachestva diagnosticheskikh mediko-biologicheskikh issledovanij [The technology of the ROC-analysis of diagnostic-quality biomedical research]. Sistemnyj analiz v medicine Proceedings of the International Scientific Conference, V.P. Kolosov (Ed.), (p. 7–10). Blagoveshchensk. [in Russian].

Vasileva, E. M. (2013) Znachenie metabolicheskikh i fermentativnykh narushenij v vozniknovenii serdechno-sosudistykh oslozhnenij u bol'nykh sakharnym diabetom 2 tipa (obzor) [The importance of metabolic and fermebtal disordes in the origin of cardiovascular complications in the patients with diabetes mellitus 2 type (review)]. Vestnik novykh medicinskikh tekhnologij, 20(2), 199–201. [in Russian].

Derzhavna sluzhba statystyky Ukrainy (2014) Zaklady okhorony zdorovia ta zakhvoriuvanist naselennia Ukrainy u 2013 rotsi [Institutions of health protection and population morbidity of Ukraine in 2013]. Kyiv. Retrieved from www.ukrstat.gov.ua. [in Ukrainian].

(2014) Nakaz Ministerstva okhorony zdorovia «Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry hostromu koronarnomu syndromi z elevatsiieiu sehmenta ST» vid 02.07.14 r. №455 [The order of the Ministry of health «On approval and implementation of medical and technological documents on standardization of medical care in acute coronary syndrome with ST-segment elevate» from 02.07.14, №. 455]. Retrieved from http://www.moz.gov.ua/ua/ portal/dn_20140702_0455.html. [in Ukrainian].

(2006) Nakaz Ministerstva okhorony zdorovia Ukrainy «Protokol nadannia medychnoi dopomohy khvorym z hostrym koronarnym syndromom bez elevatsii ST» vid 03.07.06 r. №436 [The order of the Ministry of Health of Ukraine «The Protocol of rendering medical care to patients with acute coronary syndrome without ST-segment elevate]. Retrieved from http://www.moz.gov.ua/ua/portal/dn_20060703_436.html. [in Ukrainian].

(2013) Sakharnyj diabet [Diabetes]. Informacionnyj byulleten′, 312. Retrieved from http://www.who.int/ru/ [in Russian].

(2015) Serdechno-sosudistye zabolevaniya [Cardiovascular diseases]. Informacionnyj byulleten′, 317. Retrieved from http://www.who.int/mediacentre/factsheets/fs317/ru/.[in Russian].

Imanaka-Yoshida, K., Yoshida, T., & Miyagawa-Tomita, S. (2014) Tenascin-C in development and disease of blood vessels. The Anatomical Record, 297(9), 1747–1757. doi: 10.1002/ar.22985.

Gaber, R., Ibrahimb, W. S., Nofalb, H. E., & Mahranc, D. S. (2015). Value of serum tenascin-C in patients with acute myocardial infarction. Alexandria Journal of Medicine. Retrieved from http://www.sciencedirect.com/science/article/pii/ S209050681500072 X. doi: 10.1016/j.ajme.2015.09.003.

Yao, H. C., Han, Q. F., Zhao, A. P., Yao, D. K., & Wang, L. X. (2013) Prognostic values of serum tenascin-C in patients with ischaemic heart disease and heart failure. Heart Lung Circulation, 22(3), 184–187. doi: 10.1016/j.hlc.2012.10.005.

How to Cite

1.
Koteliukh MY. A model for prognosis of development of left ventricular systolic dysfunction in patients with acute myocardial infarction and type 2 diabetes mellitus taking into account tenascin C level. Zaporozhye Medical Journal [Internet]. 2016May23 [cited 2024Jul.21];18(2). Available from: http://zmj.zsmu.edu.ua/article/view/69169

Issue

Section

Original research